-
Journal of Clinical Pharmacology Apr 1987
-
Annali Italiani Di Medicina Interna :... 1990Sulphasalazine (SLZ) has proved to be a drug effective in inducing clinical improvement or remission in chronic inflammatory rheumatic diseases (other than inflammatory... (Review)
Review
Sulphasalazine (SLZ) has proved to be a drug effective in inducing clinical improvement or remission in chronic inflammatory rheumatic diseases (other than inflammatory bowel diseases) such as rheumatoid arthritis (RA) and some seronegative spondyloarthropathies, in a fashion similar to that of long-acting, second-line drugs in RA. Several clinical studies agree upon the efficacy of the compound employed at a dose of 2-3 g/day and upon the incidence of side effects, which appear to be equivalent to or lower than those related to traditional disease-modifying drugs employed in RA. The following points should be clarified and developed with regard to the use of SLZ in chronic rheumatic diseases: main mechanism(s) of action, improvement of therapeutic strategy (i.e.: combined treatments, maintenance therapy), prevention and control of main side effects, and its preferential use or limits in the management of a larger number of inflammatory rheumatic diseases.
Topics: Arthritis, Rheumatoid; Humans; Rheumatic Diseases; Spondylitis; Spondylitis, Ankylosing; Sulfasalazine
PubMed: 1981136
DOI: No ID Found -
The Journal of Rheumatology. Supplement Sep 1988Although the incidence of side effects associated with sulfasalazine is in the range of 20%, most of the common side effects, including gastrointestinal reactions and... (Review)
Review
Although the incidence of side effects associated with sulfasalazine is in the range of 20%, most of the common side effects, including gastrointestinal reactions and headache, can be managed by dosage adjustment. In patients who experience allergic reactions of rash, fever, and arthralgia, therapy can usually be resumed after a program of desensitization. The risks associated with chronic low-grade hemolysis can be avoided by careful monitoring and, when necessary, folic acid supplementation. Certain idiosyncratic reactions to sulfasalazine do, however, represent absolute contraindications to further use of the drug. Sulfasalazine may cause reversible male infertility, but it is entirely safe for use during pregnancy and lactation. Overall, sulfasalazine has a long and impressive safety record, provided the drug is used with an awareness and appreciation of its potential pitfalls.
Topics: Drug Hypersensitivity; Humans; Inflammatory Bowel Diseases; Sulfasalazine
PubMed: 2903923
DOI: No ID Found -
Journal of Toxicology. Clinical... 1991Sulfasalazine (salicylazosulfapyridine, Azulfidine) has been widely used over the last half century for inflammatory bowel diseases, but overdose has not been reported....
Sulfasalazine (salicylazosulfapyridine, Azulfidine) has been widely used over the last half century for inflammatory bowel diseases, but overdose has not been reported. A 23 year-old male ingested 25 g of sulfasalazine in a suicide attempt. He underwent prompt treatment and survived with no ill-effects.
Topics: Adult; Crohn Disease; Depressive Disorder; Drug Overdose; Humans; Male; Suicide, Attempted; Sulfasalazine
PubMed: 1684211
DOI: 10.3109/15563659109025753 -
Hypertension in Pregnancy Feb 2022
Letter by Lu et al. regarding article, "Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia".
Topics: Esomeprazole; Female; Humans; Placenta; Pre-Eclampsia; Pregnancy; Sulfasalazine; Vascular Endothelial Growth Factor Receptor-1
PubMed: 34978249
DOI: 10.1080/10641955.2021.2024224 -
La Clinica Terapeutica 1997Sulphasalazine (SSZ) is now recognised to be a useful agent in the management of rheumatoid arthritis (RA). We studied SSZ toxicity (2 g/die) and duration of therapy in... (Clinical Trial)
Clinical Trial Review
Sulphasalazine (SSZ) is now recognised to be a useful agent in the management of rheumatoid arthritis (RA). We studied SSZ toxicity (2 g/die) and duration of therapy in 102 patients with RA. Adverse events occurred in 25.4% of all patients. In all patients the reactions subsided on either discontinuation of the drug or decrease of the dose. Gastrointestinal was the most common. At 5 years of follow-up the percentage of patients treated with SSZ still on drug was 29%, the inefficacy was 40% of the total drop-out.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Sulfasalazine
PubMed: 9377840
DOI: No ID Found -
Zhonghua Nei Ke Za Zhi Apr 1990
Review
Topics: Arthritis, Rheumatoid; Humans; Spondylitis, Ankylosing; Sulfasalazine
PubMed: 1977564
DOI: No ID Found -
Nederlands Tijdschrift Voor Geneeskunde Jan 1988
Review
Topics: Dose-Response Relationship, Drug; Humans; Rheumatic Diseases; Sulfasalazine
PubMed: 2893300
DOI: No ID Found -
Orvosi Hetilap Jan 1989In the past few years several reports have been published on the favourable effect of sulphasalazine in ankylosing spondylitis. This induced us to compare sulphasalazine... (Clinical Trial)
Clinical Trial Randomized Controlled Trial Review
In the past few years several reports have been published on the favourable effect of sulphasalazine in ankylosing spondylitis. This induced us to compare sulphasalazine with placebo in a prospective, randomized single-blind trial in 63 patients with active ankylosing spondylitis. After termination of the 24 week course of treatment significant improvement was registered in several clinical parameters both in the group taking the active drug (31 patients) and in that on placebo (32 patients). The advantage of sulphasalazine over placebo only proved to be significant in the duration of articular morning stiffness and in reducing disturbances of sleep. Observations claiming sulphasalazine to act as a remission inducing drug for ankylosing spondylitis have neither been confirmed nor ruled out by our experiences. Accurate appraisal of the effectiveness of sulphasalazine still calls for further extensive placebo-controlled double-blind studies.
Topics: Adult; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Male; Middle Aged; Placebos; Spondylitis, Ankylosing; Sulfasalazine
PubMed: 2563308
DOI: No ID Found -
Journal of the American Academy of... May 1989In an open study, 32 patients with moderate to severe stable plaque psoriasis were treated with sulfasalazine, 3 gm daily for 8 weeks. Twenty-four patients completed the...
In an open study, 32 patients with moderate to severe stable plaque psoriasis were treated with sulfasalazine, 3 gm daily for 8 weeks. Twenty-four patients completed the study, and 19 had modest to marked improvement or clearing. If confirmed by a double-blind study, sulfasalazine could become an alternative therapy in some patients with moderate to severe psoriasis.
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Psoriasis; Sulfasalazine
PubMed: 2565921
DOI: 10.1016/s0190-9622(89)70092-x